DOI: https://doi.org/10.22263/2312-4156.2021.5.7
Medvedeva L.M.
Some aspects of pathogenesis and treatment of age-related macular degeneration
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2021;20(5):7-14.
Abstract.
Age-related macular degeneration (AMD) leads to a marked decrease in central vision and disrupts social and work activities of a person. This pathology is associated with age, and its clinically significant manifestations are determined in the age group from 66 to 74 years in 15% of the population, from 75 to 84 years – in 25%, from 85 years and older – in 30%. The pathogenesis of this disease is not fully understood. But the role of certain genes in the development of age-related macular degeneration has already been proved: PLEKHA1, HTRA1, CFH, CFB / C2, CRP, complement C3, ARMS2, HMCN1 / FBLN6, FBLN5, TLR3, ApoE, VEGF A and others. New genes, presumably related to AMD, continue to be investigated, for example, PLCG 2, which codes the enzyme phospholipase C. The only effective pathogenetic treatment of neovascular AMD nowadays is anti-VEGF therapy in the form of intravitreal injections. New promising areas of treatment appear: prolonged drugs (brolucizumab), combination therapy (inhibitors of the components of the complement system and anti-VEGF therapy), many of them being at various stages of clinical trials. Further study of the pathogenesis of AMD is aimed at the development of a new, more effective treatment.
Key words: age-related macular degeneration, pathogenesis, gene polymorphism, VEGF, anti- VEGF therapy, intravitreal injection.
References
1. Fedotova TS, Khokkanen VM, Trofimova SV, Dautova ZA. Modern approach to the treatment of dry age-related macular degeneration. Med Vestn Bashkartostana. 2014;9(2):141-4. (In Russ.)
2. Fedotova TS, Khokkanen VM, Trofimova SV. Pathogenetic aspects of age-related macular degeneration of the retina. Vestn OGU. 2014;(12):325-30. (In Russ.)
3. Egorov EA, Romanenko IA. Age-related macular degeneration. Questions of pathogenesis, diagnosis and treatment. Klin Oftal'mologiia. 2009;10(1):42-6. (In Russ.)
4. Izmailov AS. Treatment of the "dry" form of age-related macular degeneration. Klin Oftal'mologiia. 2017;17(1):56-60. (In Russ.)
5. Belekhova SG, Astakhov IuS. The role of genetically determined factors in the pathogenesis of age-related macular degeneration. Oftal'mol Ved. 2015;8(4):30-9. (In Russ.)
6. Bikbov MM, Faizrakhmanov RR, Iarmukhametova AL. Age-related macular degeneration. Moscow, RF: Aprel'; 2013. 196 р. (In Russ.)
7. Efendieva MKh, Budzinskaia MV. Comparison of the characteristics of pathological changes in dry form of age-related macular degeneration according to optical coherence tomography and fundus autofluorescence. Prakt Meditsina. 2017;(3):108-10. (In Russ.)
8. Doga AV, Pedanova EK, Volodin PL, Maiorova AM. Modern aspects of diagnosis and treatment of polypoid choroidal vasculopathy. Oftal'mokhirurgiia. 2017;(1):88-92. (In Russ.)
9. Micklisch S, Lin Y, Jacob S, Karlstetter M, Dannhausen K, Dasari P, et al. Age-related macular degeneration associated polymorphism rs 10490924 in ARMS2 results in deficiency of a complement activator. J Neuroinflammation. J Neuroinflammation. 2017 Jan;14(1):4. doi: http://dx.doi.org/10.1186/s12974-016-0776-3
10. Abdulaeva EA. The role of the complement system and other inflammatory factors in the development of age-related macular degeneration. Kazan Med Zhurn. 2018;99(4):657-64. (In Russ.)
11. Kortvely E, Hauck SM, Duetsch G, Gloeckner CJ, Kremmer E, Alge-Priglinger CS, et al. ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010 Jan;51(1):79-88. doi: http://dx.doi.org/10.1167/iovs.09-3850
12. Shoshany N, Weiner C, Safir M, Einan-Lifshitz A, Pokroy R, Kol A, et al. Rare genetic variants in jewish patients suffering from age-related macular degeneration. Genes (Basel). 2019 Oct;10(10):825. doi: http://dx.doi.org/10.3390/genes10100825
13. Liao SM, Zheng W, Zhu J, Lewis CA, Delgado O, Crowley MA, et al. Specific correlation between the major chromosome 10q26 haplotype conferring risk for age-related macular degeneration and the expression of HTRA1. Mol Vis. 2017 Jun;23:318-333.
14. Maugeri A, Barchitta M, Mazzone MG, Giuliano F, Agodi A. Complement system and age-related macular degeneration: implications of gene-environment interaction for preventive and personalized medicine. Biomed Res Int. 2018 Aug;2018:7532507. doi: http://dx.doi.org/10.1155/2018/7532507
15. Lambert NG, ElShelmani H, Singh MK, Mansergh FC, Wride MA, Padilla M, et al. Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res. 2016 Sep;54:64-102. doi: http://dx.doi.org/10.1016/j.preteyeres.2016.04.003
16. Lotery AJ, Baas D, Ridley C, Jones RPO, Klaver CCW, Stone E, et al. Reduced secretion of fibulin 5 in age-related macular degeneration and cutis laxa. Hum Mutat. 2006 Jun;27(6):568-74. doi: http://dx.doi.org/10.1002/humu.20344
17. Kapetanopoulos A, Fresser F, Millonig G, Shaul Y, Baier G, Utermann G. Direct interaction of the extracellular matrix protein DANCE with apolipoprotein (a) mediated by the kringle IV-type 2 domain. Mol Genet Genomics. 2002 Jun;267(4):440-6. doi: http://dx.doi.org/10.1007/s00438-002-0673-6
18. Ma L, Tang FY, Chu WK, Young AL, Brelen ME, Pang CP, et al. Association of Toll-like receptor 3 polymorpfism rs3775291 with age-related macular degeneration: a systematic review and meta-analysis. Sci Rep. 2016 Jan;6:19718. doi: http://dx.doi.org/10.1038/srep19718
19. Cho Y, Wang JJ, Chew EY, Ferris FL, Mitchell P, Chan C-C, et al. Toll-like receptor polymorpfism and age-related macular degeneration: replication in three case-control samples. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5614-8. doi: http://dx.doi.org/10.1167/iovs.09-3688
20. Xiying M, Wenbo W, Wangyi F, Qinghuai L. Association of apolipoprotein E polymorphisms with age-related macular degeneration subtypes: an updated systematic review and meta-analysis. Arch Med Res. 2017 May;48(4):370-377. doi: http://dx.doi.org/10.1016/j.arcmed.2017.08.002
21. Liutkeviciene R, Vilkeviciute A, Smalinskiene A, Tamosiunas A, Petkeviciene J, Zaliuniene D, et al. The role of apolipoprotein E (rs7412 and rs 429358) in age-related macular degeneration. Ophthalmic Genet. 2018 Aug;39(4):457-462. doi: http://dx.doi.org/10.1080/13816810.2018.1479429
22. Waksmunski AR, Grunin M, Kinzy TG, Igo RP, Haines JL, Bailey JNC. Pathway analysis integrating genome-wide and functional data identifies PLCG2 as a candidate gene for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):4041-4051. doi: http://dx.doi.org/10.1167/iovs.19-27827
23. Sychev DA, Moshetova LK, Osmanova ER, Turkina KI, Grishina EA, Ryzhikova KA. VEGF-A gene polymorphism and the risk of developing the wet form of age-related macular degeneration. Molekuliar Meditsina. 2018;16(5):41-4. (In Russ.)
24. Shevchenko AV, Prokofev VF, Konenkov VI, Chernykh VV, Eremina AV, Dudnikova LV, i dr. A network approach to the analysis of loci of quantitative traits of tumor necrosis factor genes (TNF α-863, TNF α-308, TNF α-238), vascular endothelial growth factor (VEGF-2578, VEGF + 936) and matrix metalloproteinases (MMP2-1306, MMP3 -1171, MMP9-1569) for age-related macular degeneration. Med Immunologiia. 2017;19(5):537-46. (In Russ.)
25. Qazi Y, Maddula S, Ambati BK. Mediators of ocular angiogenesis. J Genet. 2009 Dec;88(4):495-515. doi: http://dx.doi.org/10.1007/s12041-009-0068-0
26. Murray IJ, Makridaki M, van der Veen RLP, Carden D, Parry NRA, Berendschot TTJM. Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity the CLEAR study. Invest Ophthalmol Vis Sci. 2013 Mar;54(3):1781-8. doi: http://dx.doi.org/10.1167/iovs.12-10715
27. Bobykin EV. Modes of application of antiangiogenic therapy for the treatment of macular diseases in ophthalmology. Literature review. Prakt Meditsina. 2018;16(5):104-11. (In Russ.)
28. Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017 Sep;124(9):1296-1304. doi: http://dx.doi.org/10.1016/j.ophtha.2017.03.057
29. Matsuda Y, Nonaka Y, Futakawa S, Imai H, Akita K, Nishihata T, et al. Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease. Mol Ther Nucleic Acids. 2019 Sep;17:819-828. doi: http://dx.doi.org/10.1016/j.omtn.2019.07.018
30. Lores-Motta L, de Jong EK, den Hollander AI. Exploring the use of molecular biomarkers for precision medicine in age-related macular degeneration. Mol Diagn Ther. 2018 Jun;22(3):315-343. doi: http://dx.doi.org/10.1007/s40291-018-0332-1
31. Wu J, Sun X. Complement system and age-related macular degeneration: drugs and challenges. Drug Des Devel Ther. 2019 Jul;13:2413-2425. doi: http://dx.doi.org/10.2147/DDDT.S206355
32. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, et al. Systemic complement ingibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014 Mar;121(3):693-701. doi: http://dx.doi.org/10.1016/j.ophtha.2013.09.044
33. Ren X, Li J, Xu X, Wang C, Cheng Y. IBI 302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys. Exp Eye Res. 2016 Apr;145:352-358. doi: http://dx.doi.org/10.1016/j.exer.2016.02.004
Information about authors:
Medvedeva L.M. – lecturer of the Chair of Ophthalmology, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 210009, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Ophthalmology. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Lyudmila M. Medvedeva.
